CAMBRIDGE, Mass., March 25, 2025--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent highlights ...

As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promising clinical efficacy, durable responses, and growing ...

One of the biggest dramas on TV isn’t expected to launch formally until later in 2025, but it’s already playing out off camera at four of the biggest media companies in the nation. NBA ...

Discord ads are integrated into the Quests system, providing rewards for user interaction. There are two types of quests: Video Quests involve watching ads, and Play Quests involve gameplay.

The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today! LONDON, GREATER LONDON, UNITED KINGDOM, March 18, 2025 /EINP ...

The multiple myeloma market is expected to grow in the upcoming years, owing to a rise in incident cases, label expansion and penetration of current therapies in earlier lines, high adoption of ...

The CAR-T will compete in the market with Bristol-Myers Squibb and bluebird bio spinout 2seventy’s Abecma (idecabtagene autoleucel), another BCMA-targeting CAR-T which was approved for a similar ...

PRINCETON, N.J. - The European Commission has approved Breyanzi, a treatment developed by Bristol Myers Squibb (NYSE:BMY), a pharmaceutical giant with $48.3 billion in revenue and an impressive 75 ...

Abecma (idecabtagene vicleucel) is a brand-name infusion prescribed for multiple myeloma in certain adults. Abecma is not known to interact with other medications or supplements. But it can ...

Despite initial caution, Carvykti's sales surged, reaching $334M in Q4 2024, driving Legend Biotech Corporation to net income and solidifying its market position. Legend's financial health is ...

Copyright 2025 The Associated Press. All Rights Reserved. Homeland Security Secretary Kristi Noem walks past journalists at the White House, Monday, March 10, 2025 ...